Bioventix (LSE:BVXP) — Market Cap & Net Worth
Market Cap & Net Worth: Bioventix (BVXP)
Bioventix (LSE:BVXP) has a market capitalization of $953.57K (GBX7.84 Billion) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #30600 globally and #817 in its home market, demonstrating a -0.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioventix's stock price GBX1500.00 by its total outstanding shares 5224860 (5.22 Million). See BVXP capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Bioventix Market Cap History: 2015 to 2026
Bioventix's market capitalization history from 2015 to 2026. Data shows growth from $555.86K to $953.57K (6.21% CAGR).
Index Memberships
Bioventix is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$927.28 Million | 0.10% | #164 of 722 |
Weight: Bioventix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioventix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioventix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.09x
Bioventix's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.16x
Bioventix's market cap is 0.16 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $624.40K | $5.52 Million | $3.49 Million | 0.11x | 0.18x |
| 2017 | $1.19 Million | $7.25 Million | $4.92 Million | 0.16x | 0.24x |
| 2018 | $1.54 Million | $8.75 Million | $5.66 Million | 0.18x | 0.27x |
| 2019 | $1.72 Million | $9.29 Million | $5.86 Million | 0.19x | 0.29x |
| 2020 | $2.37 Million | $10.31 Million | $7.20 Million | 0.23x | 0.33x |
| 2021 | $1.91 Million | $10.93 Million | $6.73 Million | 0.17x | 0.28x |
| 2022 | $2.34 Million | $11.72 Million | $7.67 Million | 0.20x | 0.31x |
| 2023 | $2.63 Million | $12.82 Million | $8.37 Million | 0.21x | 0.31x |
| 2024 | $2.02 Million | $13.61 Million | $8.10 Million | 0.15x | 0.25x |
| 2025 | $1.21 Million | $13.12 Million | $7.58 Million | 0.09x | 0.16x |
Competitor Companies of BVXP by Market Capitalization
Companies near Bioventix in the global market cap rankings as of August 7, 2026.
Key companies related to Bioventix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Bioventix Historical Marketcap From 2015 to 2026
Between 2015 and today, Bioventix's market cap moved from $555.86K to $ 953.57K, with a yearly change of 6.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX953.57K | -21.26% |
| 2025 | GBX1.21 Million | -40.00% |
| 2024 | GBX2.02 Million | -23.26% |
| 2023 | GBX2.63 Million | +12.23% |
| 2022 | GBX2.34 Million | +22.87% |
| 2021 | GBX1.91 Million | -19.36% |
| 2020 | GBX2.37 Million | +37.24% |
| 2019 | GBX1.72 Million | +11.86% |
| 2018 | GBX1.54 Million | +29.21% |
| 2017 | GBX1.19 Million | +90.98% |
| 2016 | GBX624.40K | +12.33% |
| 2015 | GBX555.86K | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Bioventix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $953.57K USD |
| MoneyControl | $953.57K USD |
| MarketWatch | $953.57K USD |
| marketcap.company | $953.57K USD |
| Reuters | $953.57K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more